Shopping Cart
Remove All
Your shopping cart is currently empty
MDR-1339 (DWK-1339) is an orally active, blood-brain-barrier-permeable inhibitor of amyloid-β (Aβ) aggregation.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $54 | In Stock | In Stock | |
| 5 mg | $127 | In Stock | In Stock | |
| 10 mg | $196 | In Stock | In Stock | |
| 25 mg | $393 | In Stock | In Stock | |
| 50 mg | $593 | In Stock | In Stock | |
| 100 mg | $892 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $97 | In Stock | In Stock |
| Description | MDR-1339 (DWK-1339) is an orally active, blood-brain-barrier-permeable inhibitor of amyloid-β (Aβ) aggregation. |
| In vitro | MDR-1339 shows no significant inhibition of a panel of CYP isozymes, while it slightly inhibits CYP2C8 (IC50: 31.4 μM). MDR-1339 (1.5-10 μM) protects cells from this Aβ-induced toxicity. MDR-1339 (3.1-50 μM) also dose-dependently blocks the formation of Aβ aggregates and disaggregates Aβ fibrils. |
| In vivo | MDR-1339 (0.1-10 mg/kg, p.o.) dose-dependently restores passive avoidance responses in Alzheimer's disease mice models (ED50: 0.19 mg/kg) and significantly improves spontaneous alternation while reducing Aβ1-40 and Aβ1-42 levels in APP/PS1 mice at 30 and 100 mg/kg, p.o. daily for 8 weeks. |
| Synonyms | DWK-1339 |
| Molecular Weight | 326.39 |
| Formula | C20H22O4 |
| Cas No. | 1018946-38-7 |
| Smiles | COCCCc1ccc2oc(cc2c1)-c1ccc(OC)c(OC)c1 |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 40 mg/mL (122.55 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.